Medicenna Therapeutics Corp
🇨🇦XTSE.MDNACanadaHealthcare
PriceCA$0.600.00 (0%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 0
- Medium: 2
- Low: 1
Overnight gap: a gap up from the prior close
52-week low: the price is trading close to this level
Long-term debt to equity: a sudden drop below its trailing quarter average
Revenue growth: reversed into decline
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA58490H1073
- CUSIP
- 58490H107
Company
- Employees
- 18
- Headquarters
- Toronto, Canada
- Website
- https://www.medicenna.com
Market
- Shares outstanding
- 92.3M
- Market cap
- CA$50.05M
Highlights
- Market cap
- CA$50.05M
- EPS LTM
- -CA$0.14calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -4.23calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$0-100%down year on year
- Net income
- -CA$13.1M+50.09%up year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$17.71M-16.9%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Medicenna Therapeutics Corp is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker MDNA. Its market capitalisation is CA$50.05M, from 92.3M shares outstanding, as of . Across the 141 trading sessions to the shares traded between CA$0.59 and CA$1.97, and the last close of CA$0.60 sits 1% of the way up that range. The company is headquartered in Toronto, Canada, and employs about 18 people.
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.